Efficacy of Alpha Lipoic Acid Supplementation In Chemotherapy-Induced Peripheral Neuropathy

Abstract

A B S T R A C T
Background. Chemotherapy-induced peripheral neuropathy is a side effect of
several chemotherapy drugs and a significant cause of chronic pain in cancer
patients, which affects patients' long-term quality of life. The neurotoxic
chemotherapy agents most reported to cause neuropathic pains are platinum and
taxane. This study aimed to determine the efficacy of alpha-lipoic acid
supplementation in chemotherapy patients. Methods. This study used a
randomized, double-blind clinical trial in the oncology haematology clinic in the
Department of Internal Medicine at Mohammad Hoesin General Hospital Palembang
from November 2018 to July 2019. Samples were taken from patients who met the
inclusion criteria and signed informed consent forms to join the study. This study
used SPSS version 22.0 for Windows to analyze the data.Results. This research
studied 30 subjects who were divided into alpha lipoic acid groups and placebo
groups with 15 samples each. The alpha-lipoic acid group showed a significant
decline in the Toronto Clinical Scoring System (TCSS) after treatment (p = 0.000)
compared to the placebo group (p = 0.164). Conclusions. Treatment with a 600 mg
single dose each day of alpha-lipoic acid for 12 weeks effectively improved patients
condition significantly.